Condition 1: Heart failure. Condition 2: Dyslipidemia. Heart failure Disorders of lipoprotein metabolism and other lipidemias
Conditions
Interventions
Intervention 1: Intervention group: The intervention group consumed one QUETROL capsule daily from Raha Pharmaceutical Company (electronic prescription system code: 92179) containing 250 mg of resvera
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age 35 to 75 years Diagnostic factors for heart failure (Ejection Fraction 150 mg/dl , HDL 130 mg/dl , TC >200 mg/dl Diabetic patients who have been diagnosed for at least 6 months. Willingness to maintain daily eating habits, physical activity patterns, and body weight throughout the study (no lifestyle changes) The BMI of the participants was between 18.5 and 30.
Exclusion criteria
Exclusion criteria: Use of any antioxidant supplement, including resveratrol, in the past 3 months Subjects with acute heart disease, cardiac surgeries and interventions within 30 days prior to randomization Patients with TG above 400 mg/dl or LDL-C above 190 mg/dl at study entry People with kidney failure (GFR less than or equal to 20) People with liver failure (ALT and AST greater than or equal to 2 times the normal limit) Failure to cooperate and follow the supplement intake protocol and having any allergies to the supplement Changes in the dose and type of medications used to control blood sugar and lipid profile during the study Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection Fraction. Timepoint: At baseline and after 12 weeks of intervention. Method of measurement: Echocardiography by a cardiologist. | — |
Secondary
| Measure | Time frame |
|---|---|
| Triglycerides (TG). Timepoint: At baseline and after 12 weeks of intervention. Method of measurement: Changes in blood triglyceride levels will be measured using blood tests with standard laboratory methods.;Total cholesterol. Timepoint: At baseline and after 12 weeks of intervention. Method of measurement: Changes in total cholesterol levels will be measured using blood tests with standard laboratory methods.;HDL-C. Timepoint: At baseline and after 12 weeks of intervention. Method of measurement: Changes in high-density lipoprotein (HDL) levels will be measured using blood tests with standard laboratory methods.;LDL-C. Timepoint: At baseline and after 12 weeks of intervention. Method of measurement: Changes in low-density lipoprotein cholesterol (LDL-C) levels will be measured using blood tests with standard laboratory methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Zarei
Kashan University of Medical Sciences
Outcome results
None listed